3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
3
Glioma
3
Colorectal Neoplasms
3
Central Nervous System Neoplasms
3
Wilms Tumor
2
Thyroid Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Multiple Myeloma
2
Melanoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Ependymoma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Interventions
Gemcitabine
45
Cisplatin
34
Oxaliplatin
23
Capecitabine
17
Fluorouracil
13
Leucovorin
12
pembrolizumab
11
lenvatinib
11
durvalumab
10
S 1 (combination)
10
Irinotecan
10
Bevacizumab
9
apatinib
7
Nivolumab
7
tremelimumab
6
Trastuzumab
5
envafolimab
4
atezolizumab
4
Injections
4
Docetaxel
4
trametinib
3
titanium silicide
3
tislelizumab
3
irinotecan sucrosofate
3
camrelizumab
3
Radiotherapy
3
Drug Therapy
3
zanidatamab
2
toripalimab
2
surufatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Biliary Tract Neoplasms
×
larotrectinib
×
Clear all
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA